Logan Stone Capital’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Logan Stone Capital’s Portfolio DMAA Stock Details DMAA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.17M	Buy	+109,959	New	+$1.16M	0.25%	63
2026 Q1	–	Sell	-10,900	Closed	-$113K	–	188
2025 Q4	$113K	Buy	+10,900	New	+$113K	0.03%	146
2025 Q3	–	Sell	-60,991	Closed	-$622K	–	96
2025 Q2	$622K	Buy	+60,991	New	+$617K	0.29%	46

Other funds holding DMAA

KIM

Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Logan Stone Capital's DMAA Position: Q2 2026 in Review

Logan Stone Capital opened a new position in Drugs Made In America Acquisition Corp (DMAA) in Q2 2026: 109,959 shares worth $1.17M. The stake represents 0.25% of the portfolio and ranks #63 among its holdings. This is a return to the name: Logan Stone Capital previously reported a position in DMAA as recently as Q4 2025.

Logan Stone Capital first reported a position in DMAA in Q2 2025 and has held it in 3 quarters since. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

Logan Stone Capital held 109,959 shares of Drugs Made In America Acquisition Corp worth $1.17M as of Q2 2026.
Drugs Made In America Acquisition Corp was a new Logan Stone Capital position in Q2 2026.
Drugs Made In America Acquisition Corp made up 0.25% of Logan Stone Capital's portfolio in Q2 2026, its #63 holding.
Logan Stone Capital first reported a position in Drugs Made In America Acquisition Corp in Q2 2025 and has held it in 3 quarters since.
23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Logan Stone Capital's 13F filing for Q2 2026, filed 14 Aug 2026.